Novo Nordisk’s Newest Weight Loss Drug May Be Its Finest But—and a A lot-Wanted Win

It’s been a topsy-turvy week for Novo Nordisk, makers of the favored weight reduction medicine Ozempic and Wegovy. Contemporary off the heels of a disappointing trial for one experimental drug, the corporate has simply reported outcomes for an additional drug that could be its greatest candidate but.

On Wednesday, Novo Nordisk revealed the topline numbers for its Section II trial of UBT251. Individuals taking UBT251 misplaced as much as roughly 20% of their baseline weight after 24 weeks—effectively above the everyday tempo of present medicine available on the market. Although nonetheless early in improvement, the findings appear to position UBT251 as one of the crucial spectacular weight problems therapies coming down the pipeline.

The long run king of weight reduction?

Novo Nordisk is growing UBT251 along side the Chinese language firm United Laboratories Worldwide Holdings Restricted (TUL). It’s a triple-agonist drug, that means it mimics the exercise of three separate hormones that regulate our starvation and metabolism: GLP-1 (the energetic ingredient in Ozempic and Wegovy), GIP, and glucagon.

The Section II trial was performed in China and concerned 205 individuals who have been overweight or obese (common physique mass index was 33.1). Individuals have been randomized to both obtain considered one of three doses of UBT251 or a placebo.

Over a 24-week span, all three therapy teams misplaced considerably extra weight than the placebo group (2% weight on common). And the best-performing misplaced as much as 19.7% of their physique weight on common. The drug additionally seemed to be secure and tolerable, with most adversarial occasions being gastrointestinal and waning over time, just like different GLP-1 medicines.

Typically, these medicine take as much as a yr to achieve their full peak of effectiveness, suggesting that UBT251’s ceiling has but to be reached. There’s not less than one different triple-agonist drug in scientific improvement, Eli Lilly’s retatrutide. In late-stage trials, individuals taking retatrutide have misplaced as much as 28% of their physique weight over a yr’s time, essentially the most impressive results seen for any weight reduction drug thus far. So it’s definitely doable that UBT251 may match and even surpass that success.

“We’re very inspired by these information from the trial in China, which reveal the potential of UBT251 and its differentiated scientific profile and security and tolerability profile,” mentioned Martin Holst Lange, govt vice chairman, chief scientific officer, and head of analysis and improvement at Novo Nordisk, in a press release from the corporate.

Novo Nordisk’s lifeline

These newest outcomes are a sorely wanted win for Novo Nordisk.

On Monday, the corporate reported outcomes from a separate trial of its experimental mixture drug CagriSema (the GLP-1 mimic semaglutide plus the amylin mimic cagrilintide). Whereas individuals who stayed on CargiSema over an 84-week span misplaced a mean of 23% of their weight, they fared worse than individuals on Eli Lilly’s already authorized drug tirzepatide, who noticed a mean of 25.5% weight reduction.

These outcomes are nonetheless higher than the everyday success seen with Novo Nordisk’s Ozempic and Wegovy, and CagriSema stays on monitor to win FDA approval this yr. However the firm’s gambit to place CagriSema as one of the best weight problems drug accessible within the close to future objectively fell flat. Unsurprisingly, following the discharge of the outcomes, Novo Nordisk’s inventory costs took a pointy drop. Since final yr, the corporate has skilled quite a few setbacks, together with hiring freezes and the departure of a number of senior members, together with its CEO.

With UBT251 coming across the nook, Novo Nordisk might not less than nonetheless have the prospect to reclaim its throne within the weight problems therapy subject. Novo Nordisk has acknowledged that it’s transferring forward with one other Section II trial of UBT251 this yr, whereas TUL will quickly begin a Section III of its personal.

All this competitors is probably going excellent news for individuals with weight problems. Extra authorized therapies will present extra choices for individuals to select from, ought to they not reply to an preliminary therapy. And traditionally, extra entries in a drug class result in decrease costs over time. That mentioned, it should take till 2030 for the primary generics of semaglutide to achieve the U.S.